Patient Voice

519  An Evolving Continuum of Care for the Kidney Disease Patient Will Help the Transplant Center Patient Navigator
Richard A. Knight
See related editorial and article on pages 529 and 620.

Editorials

521  Community-Based CKD Screening in Black Americans
Keith C. Norris and Susanne B. Nicholas
See related article on page 551.

524  Clear the Fog around Parathyroid Hormone Assays: What Do iPTH Assays Really Measure?
Berthold Hocher and Shufei Zeng
See related article on page 569.

527  The Role of Bicarbonate in Cognition: Acidosis May Be Corrosive to the Brain
Stephen M. Sozio and Mara McAdams-DeMarco
See related article on page 596.

529  What Else Can We Do to Ensure Transplant Equity for High-Risk Patients?
Amy D. Waterman and Jennifer L. Beaumont
See related Patient Voice and article on pages 519 and 620.

Original Articles

Acute Kidney Injury and ICU Nephrology

531  Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients

542  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury
Todd A. Miano, Ebbing Lautenbach, F. Perry Wilson, Wensheng Guo, Yuliya Borovskiy, and Sean Hennessy

Chronic Kidney Disease

551  Black Americans’ Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease
Ebele M. Umeukeje, Marcus G. Wild, Saugar Maripuri, Teresa Davidson, Margaret Rutherford, Khaled Abdel-Kader, Julia Lewis, Consuelo H. Wilkins, and Kerri Cavanaugh
See related editorial on page 521.

560  Associations of Plasma Amino Acid and Acylcarnitine Profiles with Incident Reduced Glomerular Filtration Rate
Feijie Wang, Liang Sun, Qi Sun, Liming Liang, Xianfu Gao, Rongxia Li, An Pan, Huaiying Li, Yueyi Deng, Frank B. Hu, Jiuru Wu, Rong Zeng, and Xu Lin

569  Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease
Sarah Seiler-Mussler, Anne S. Limbach, Insa E. Emrich, John W. Pickering, Heinz J. Roth, Danilo Fliser, and Gunnar H. Heine
See related editorial on page 524.
Chronic Kidney Disease (Continued)

577 **Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients**
Milica Bozic, Angels Betriu, Marcelino Bermudez-Lopez, Alberto Ortiz, Elvira Fernandez, Jose M. Valdivielso, and on behalf of the NEFRONA investigators

Hypertension

585 **Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease**
Mahboob Rahman, Jesse Yenchih Hsu, Niraj Desai, Chi-yuan Hsu, Amanda H. Anderson, Lawrence J. Appel, Jing Chen, Debbie L. Cohen, Paul E. Drawz, Jiang He, Pan Qiang, Ana C. Ricardo, Susan Steigerwalt, Matthew R. Weir, Jackson T. Wright Jr., Xiaoming Zhang, and Raymond R. Townsend, for the CRIC Study Investigators

596 **Serum Bicarbonate Concentration and Cognitive Function in Hypertensive Adults**
See related editorial on page 527.

Maintenance Dialysis

604 **β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial**
Alvin Tieu, Thomas J. Velenosi, Andrew S. Kucey, Matthew A. Weir, and Bradley L. Urquhart

Nephrolithiasis

612 **Metabolic and Hypertensive Complications of Pregnancy in Women with Nephrolithiasis**
Jessica Sheehan Tangren, Camille E. Powe, Jeffrey Ecker, Kate Bramham, Elizabeth Ankers, S. Ananth Karumanchi, and Ravi Thadhani

Transplantation

620 **Transplant Center Patient Navigator and Access to Transplantation among High-Risk Population: A Randomized, Controlled Trial**
See related Patient Voice and editorial on pages 519 and 529.

628 **Association of Serious Fall Injuries among United States End Stage Kidney Disease Patients with Access to Kidney Transplantation**
Laura C. Plantinga, Raymond J. Lynch, Rachel E. Patzer, Stephen O. Pastan, and C. Barrett Bowling

Research Letter

638 **Correlation of Urine Ammonium and Urine Osmolal Gap in Kidney Transplant Recipients**
Kalani L. Raphael and Joachim H. Ix

Evidence-Based Nephrology

641 **Treatment of Severe Hyponatremia**
Richard H. Sterns
See related commentary on page 650.

Commentary

650 **Commentary on Treatment of Severe Hyponatremia**
Stephen Seliger and Bryan Kestenbaum
See related article on page 641.

Kidney Case Conference: How I Treat

652 **Evaluation and Management of CKD in the Nonkidney Solid Organ Transplant Recipient**
Karen M. Warburton and Alden M. Doyle
On the Cover

*What’s the diagnosis?*

We report a case of a 66-year-old man with history of recurrent sinusitis, asthma, hepatitis C and hepatitis B who presented with gait instability, progressive lower extremity edema and dyspnea. He was found to have AKI with serum creatinine of 2.0 mg/dL (baseline 0.8 mg/dL) and WBCs count of 10.2 with peripheral eosinophilia 23%. Urinalysis was positive for proteinuria (2+) and mild hematuria without dysmorphic RBCs or RBCs casts. Urine protein/creatinine ratio was 1.8 g. Kidney ultrasound was unremarkable. Hepatitis B and HIV viral loads were undetectable. Complement levels were normal. RF and serum cryoglobulin were negative. Patient had positive p-ANCA (1:640) and MPO antibodies (1:103). Other serologies were negative. CT of the chest showed multiple lung nodules. Kidney biopsy demonstrated evidence of eosinophilic granulomatosis with polyangiitis (EGPA) along with arteritis, crescents and necrotizing GN. Patient received cyclophosphamide and prednisone. The patient’s serum creatinine returned to baseline and protein/creatinine ratio improved to 0.6 g.

Figures 1 and 2 demonstrate diffuse interstitial inflammation with eosinophils, identifiable by their characteristic H&E staining pattern. Specifically the eosin, an acidic dye which is negatively charged, stains the basic cytoplasm of these cells a granular pink color. Focal necrotizing arteritis with eosinophils are also seen in figure 1. Figure 3 shows glomerulonephritis with focal crescents using silver stain. EGPA is necrotizing vasculitis that affect small and medium vessels. Clinical manifestations can include asthma, sinusitis, lung infiltrates/nodules, neuropathy, and glomerulonephritis. Diagnosis is confirmed by biopsy. Treatment is a combination of prednisone and cyclophosphamide or rituximab.

*(Images and text provided by Mohamad Hanouneh, MD, Diana S. Najjar, MD, and Duvuru Geetha, MBBS, MD, Johns Hopkins University, Department of Medicine, Baltimore, Maryland)*